Mereo BioPharma Group Ownership 2024 | Who Owns Mereo BioPharma Group Now?
Institutional Ownership
14.35%
Insider Ownership
1.03%
Retail Ownership
84.62%
Institutional Holders
78.00
Mereo BioPharma Group Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RUBRIC CAPITAL MANAGEMENT LP | 2.19% | 1.44% | 15,307,347 | 1,754,350 | 12.94% | 55,106,449 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.68% | 0.08% | 11,791,310 | 2,462,571 | 26.40% | 42,448,716 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 1.33% | 1.01% | 9,283,492 | 1,141,383 | 14.02% | 33,420,571 | Jun 30, 2024 |
| MANGROVE PARTNERS | 1.25% | 2.42% | 8,752,893 | - | - | 31,510,415 | Jun 30, 2024 |
| JANUS HENDERSON GROUP PLC | 1.13% | 0.02% | 7,880,882 | 2,760,309 | 53.91% | 28,410,580 | Jun 30, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 0.96% | 0.40% | 6,710,429 | 6,710,429 | 100.00% | 24,157,544 | Jun 30, 2024 |
| 683 CAPITAL MANAGEMENT, LLC | 0.71% | 1.36% | 5,000,000 | -750,000 | -13.04% | 18,000,000 | Jun 30, 2024 |
| ALKEON CAPITAL MANAGEMENT LLC | 0.67% | 0.03% | 4,698,100 | 460,000 | 10.85% | 16,913,160 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 0.63% | 0.74% | 4,401,371 | 4,401,371 | 100.00% | 15,844,936 | Jun 30, 2024 |
| CLEARLINE CAPITAL LP | 0.48% | 0.33% | 3,326,718 | - | - | 11,976,185 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.46% | 0.01% | 3,201,705 | 1,022,570 | 46.93% | 11,526,138 | Jun 30, 2024 |
| TEJARA CAPITAL LTD | 0.37% | 3.42% | 2,615,458 | 145,274 | 5.88% | 9,415,649 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.36% | 0.00% | 2,507,513 | 263,699 | 11.75% | 9,027,047 | Jun 30, 2024 |
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.25% | 0.61% | 1,775,000 | 825,000 | 86.84% | 6,390,000 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.25% | 0.01% | 1,762,003 | 89,694 | 5.36% | 6,343,211 | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | 0.18% | 0.11% | 1,253,250 | 1,253,250 | 100.00% | 4,511,700 | Jun 30, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.18% | 0.40% | 1,246,953 | -1,370,000 | -52.35% | 4,489,031 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.16% | 0.01% | 1,144,051 | 1,144,051 | 100.00% | 4,118,584 | Jun 30, 2024 |
| NEOS INVESTMENT MANAGEMENT LLC | 0.14% | 0.14% | 959,467 | 336,037 | 53.90% | 3,454,081 | Jun 30, 2024 |
| BLUE OWL CAPITAL HOLDINGS LP | 0.13% | 0.90% | 897,809 | 897,809 | 100.00% | 3,232,112 | Jun 30, 2024 |
Mereo BioPharma Group's largest institutional shareholder is RUBRIC CAPITAL MANAGEMENT LP, holding 2.19% of the company's total share outstanding, currently valued at $55.11M. The top 10 institutional shareholders own together 11.02% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| TEJARA CAPITAL LTD | 0.37% | 3.42% | 2,615,458 | 145,274 | 5.88% | 9,415,649 | Jun 30, 2024 |
| MANGROVE PARTNERS | 1.25% | 2.42% | 8,752,893 | - | - | 31,510,415 | Jun 30, 2024 |
| ACUTA CAPITAL PARTNERS, LLC | 0.10% | 2.05% | 677,000 | 279,116 | 70.15% | 2,437,200 | Jun 30, 2024 |
| RUBRIC CAPITAL MANAGEMENT LP | 2.19% | 1.44% | 15,307,347 | 1,754,350 | 12.94% | 55,106,449 | Jun 30, 2024 |
| 683 CAPITAL MANAGEMENT, LLC | 0.71% | 1.36% | 5,000,000 | -750,000 | -13.04% | 18,000,000 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 1.33% | 1.01% | 9,283,492 | 1,141,383 | 14.02% | 33,420,571 | Jun 30, 2024 |
| BLUE OWL CAPITAL HOLDINGS LP | 0.13% | 0.90% | 897,809 | 897,809 | 100.00% | 3,232,112 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 0.63% | 0.74% | 4,401,371 | 4,401,371 | 100.00% | 15,844,936 | Jun 30, 2024 |
| KNOLL CAPITAL MANAGEMENT, LLC | 0.04% | 0.63% | 260,470 | - | - | 937,692 | Jun 30, 2024 |
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.25% | 0.61% | 1,775,000 | 825,000 | 86.84% | 6,390,000 | Jun 30, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 0.96% | 0.40% | 6,710,429 | 6,710,429 | 100.00% | 24,157,544 | Jun 30, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.18% | 0.40% | 1,246,953 | -1,370,000 | -52.35% | 4,489,031 | Jun 30, 2024 |
| KNOTT DAVID M JR | 0.03% | 0.34% | 236,000 | 206,000 | 686.67% | 850,000 | Jun 30, 2024 |
| CLEARLINE CAPITAL LP | 0.48% | 0.33% | 3,326,718 | - | - | 11,976,185 | Jun 30, 2024 |
| ARTIA GLOBAL PARTNERS LP | 0.06% | 0.29% | 421,359 | - | - | 1,516,892 | Jun 30, 2024 |
| MONACO ASSET MANAGEMENT SAM | 0.05% | 0.20% | 348,128 | -56,872 | -14.04% | 1,253,261 | Jun 30, 2024 |
| CANTOR FITZGERALD, L. P. | 0.04% | 0.20% | 275,000 | 275,000 | 100.00% | 990,000 | Jun 30, 2024 |
| NEOS INVESTMENT MANAGEMENT LLC | 0.14% | 0.14% | 959,467 | 336,037 | 53.90% | 3,454,081 | Jun 30, 2024 |
| EVERSEPT PARTNERS, LP | 0.07% | 0.12% | 496,171 | 496,171 | 100.00% | 1,786,216 | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | 0.18% | 0.11% | 1,253,250 | 1,253,250 | 100.00% | 4,511,700 | Jun 30, 2024 |
The largest Mereo BioPharma Group shareholder by % of total assets is TEJARA CAPITAL LTD. The company owns 2.62M shares of Mereo BioPharma Group (MREO), representing 3.42% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 0.96% | 0.40% | 6,710,429 | 6,710,429 | 100.00% | 24,157,544 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 0.63% | 0.74% | 4,401,371 | 4,401,371 | 100.00% | 15,844,936 | Jun 30, 2024 |
| JANUS HENDERSON GROUP PLC | 1.13% | 0.02% | 7,880,882 | 2,760,309 | 53.91% | 28,410,580 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.68% | 0.08% | 11,791,310 | 2,462,571 | 26.40% | 42,448,716 | Jun 30, 2024 |
| RUBRIC CAPITAL MANAGEMENT LP | 2.19% | 1.44% | 15,307,347 | 1,754,350 | 12.94% | 55,106,449 | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | 0.18% | 0.11% | 1,253,250 | 1,253,250 | 100.00% | 4,511,700 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.16% | 0.01% | 1,144,051 | 1,144,051 | 100.00% | 4,118,584 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 1.33% | 1.01% | 9,283,492 | 1,141,383 | 14.02% | 33,420,571 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.46% | 0.01% | 3,201,705 | 1,022,570 | 46.93% | 11,526,138 | Jun 30, 2024 |
| BLUE OWL CAPITAL HOLDINGS LP | 0.13% | 0.90% | 897,809 | 897,809 | 100.00% | 3,232,112 | Jun 30, 2024 |
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.25% | 0.61% | 1,775,000 | 825,000 | 86.84% | 6,390,000 | Jun 30, 2024 |
| EVERSEPT PARTNERS, LP | 0.07% | 0.12% | 496,171 | 496,171 | 100.00% | 1,786,216 | Jun 30, 2024 |
| ALKEON CAPITAL MANAGEMENT LLC | 0.67% | 0.03% | 4,698,100 | 460,000 | 10.85% | 16,913,160 | Jun 30, 2024 |
| NEOS INVESTMENT MANAGEMENT LLC | 0.14% | 0.14% | 959,467 | 336,037 | 53.90% | 3,454,081 | Jun 30, 2024 |
| ACUTA CAPITAL PARTNERS, LLC | 0.10% | 2.05% | 677,000 | 279,116 | 70.15% | 2,437,200 | Jun 30, 2024 |
| CANTOR FITZGERALD, L. P. | 0.04% | 0.20% | 275,000 | 275,000 | 100.00% | 990,000 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.36% | 0.00% | 2,507,513 | 263,699 | 11.75% | 9,027,047 | Jun 30, 2024 |
| KNOTT DAVID M JR | 0.03% | 0.34% | 236,000 | 206,000 | 686.67% | 850,000 | Jun 30, 2024 |
| POLAR ASSET MANAGEMENT PARTNERS INC. | 0.02% | 0.01% | 145,800 | 145,800 | 100.00% | 524,880 | Jun 30, 2024 |
| TEJARA CAPITAL LTD | 0.37% | 3.42% | 2,615,458 | 145,274 | 5.88% | 9,415,649 | Jun 30, 2024 |
As of Jun 30 2024, Mereo BioPharma Group's largest institutional buyer is DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C). The company purchased 6.71M stocks of MREO, valued at $24.16M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 0.01% | 0.01% | 75,000 | -3,578,494 | -97.95% | 270,000 | Jun 30, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.18% | 0.40% | 1,246,953 | -1,370,000 | -52.35% | 4,489,031 | Jun 30, 2024 |
| MORGAN STANLEY | 0.03% | 0.00% | 207,736 | -1,174,953 | -84.98% | 747,850 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | - | - | - | -991,971 | -100.00% | - | Jun 30, 2024 |
| 683 CAPITAL MANAGEMENT, LLC | 0.71% | 1.36% | 5,000,000 | -750,000 | -13.04% | 18,000,000 | Jun 30, 2024 |
| ABRDN PLC | 0.01% | 0.00% | 73,168 | -744,141 | -91.05% | 263,405 | Jun 30, 2024 |
| VERITION FUND MANAGEMENT LLC | 0.03% | 0.00% | 226,494 | -258,942 | -53.34% | 815,378 | Jun 30, 2024 |
| EAM GLOBAL INVESTORS LLC | - | - | - | -195,087 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.03% | 0.00% | 201,776 | -149,953 | -42.63% | 726,394 | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | - | - | - | -148,000 | -100.00% | - | Jun 30, 2024 |
| FRED ALGER MANAGEMENT, LLC | 0.01% | 0.00% | 49,304 | -145,575 | -74.70% | 177,494 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | - | - | - | -126,500 | -100.00% | - | Jun 30, 2024 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.00% | - | 14,621 | -104,357 | -87.71% | 52,636 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.00% | 0.00% | 33,287 | -76,040 | -69.55% | 119,833 | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | - | - | - | -75,787 | -100.00% | - | Jun 30, 2024 |
| MONACO ASSET MANAGEMENT SAM | 0.05% | 0.20% | 348,128 | -56,872 | -14.04% | 1,253,261 | Jun 30, 2024 |
| ENVESTNET ASSET MANAGEMENT INC | - | - | - | -55,903 | -100.00% | - | Jun 30, 2024 |
| J. GOLDMAN & CO LP | 0.03% | 0.02% | 227,890 | -50,698 | -18.20% | 820,404 | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | - | - | - | -47,030 | -100.00% | - | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.00% | - | 365 | -37,757 | -99.04% | 1,314 | Jun 30, 2024 |
As of Jun 30 2024, Mereo BioPharma Group's biggest institutional seller is SUVRETTA CAPITAL MANAGEMENT, LLC. The company sold -3.58M shares of MREO, valued at $270.00K.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 0.96% | 0.40% | 6,710,429 | 6,710,429 | 100.00% | 24,157,544 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 0.63% | 0.74% | 4,401,371 | 4,401,371 | 100.00% | 15,844,936 | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | 0.18% | 0.11% | 1,253,250 | 1,253,250 | 100.00% | 4,511,700 | Jun 30, 2024 |
| BLUE OWL CAPITAL HOLDINGS LP | 0.13% | 0.90% | 897,809 | 897,809 | 100.00% | 3,232,112 | Jun 30, 2024 |
| EVERSEPT PARTNERS, LP | 0.07% | 0.12% | 496,171 | 496,171 | 100.00% | 1,786,216 | Jun 30, 2024 |
| CANTOR FITZGERALD, L. P. | 0.04% | 0.20% | 275,000 | 275,000 | 100.00% | 990,000 | Jun 30, 2024 |
| POLAR ASSET MANAGEMENT PARTNERS INC. | 0.02% | 0.01% | 145,800 | 145,800 | 100.00% | 524,880 | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.01% | 0.04% | 55,400 | 55,400 | 100.00% | 199,440 | Jun 30, 2024 |
| GOLDEN STATE EQUITY PARTNERS | 0.00% | 0.02% | 24,800 | 24,800 | 100.00% | 89,280 | Jun 30, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.00% | 0.00% | 13,926 | 13,926 | 100.00% | 50,134 | Jun 30, 2024 |
| ADVISER INVESTMENTS LLC | 0.00% | 0.00% | 12,550 | 12,550 | 100.00% | 45,180 | Jun 30, 2024 |
| PNC FINANCIAL SERVICES GROUP, INC. | 0.00% | - | 4,524 | 4,524 | 100.00% | 16,286 | Jun 30, 2024 |
Mereo BioPharma Group's largest new institutional shareholder by number of shares is DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), purchased 6.71M shares, valued at $24.16M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | - | - | - | -991,971 | -100.00% | - | Jun 30, 2024 |
| EAM GLOBAL INVESTORS LLC | - | - | - | -195,087 | -100.00% | - | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | - | - | - | -148,000 | -100.00% | - | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | - | - | - | -126,500 | -100.00% | - | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | - | - | - | -75,787 | -100.00% | - | Jun 30, 2024 |
| ENVESTNET ASSET MANAGEMENT INC | - | - | - | -55,903 | -100.00% | - | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | - | - | - | -47,030 | -100.00% | - | Jun 30, 2024 |
| INDEX FUND ADVISORS, INC. | - | - | - | -30,000 | -100.00% | - | Jun 30, 2024 |
| TUDOR INVESTMENT CORP ET AL | - | - | - | -26,179 | -100.00% | - | Jun 30, 2024 |
| SG AMERICAS SECURITIES, LLC | - | - | - | -16,221 | -100.00% | - | Jun 30, 2024 |
| GTS SECURITIES LLC | - | - | - | -15,664 | -100.00% | - | Jun 30, 2024 |
| TOTAL CLARITY WEALTH MANAGEMENT, INC. | - | - | - | -11,860 | -100.00% | - | Jun 30, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -7,145 | -100.00% | - | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | - | - | - | -1,900 | -100.00% | - | Jun 30, 2024 |
| ICA GROUP WEALTH MANAGEMENT, LLC | - | - | - | -1,000 | -100.00% | - | Jun 30, 2024 |
Mereo BioPharma Group's largest sold out institutional shareholder by shares sold is PRICE T ROWE ASSOCIATES INC /MD/, sold -0.99M shares, valued at -, as of undefined.
Mereo BioPharma Group Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Tema ETF Trust | 11.69% | 521,779 | 206,498 | 65.50% | Feb 29, 2024 |
| TEKLA HEALTHCARE INVESTORS | 0.65% | 560,468 | -503,331 | -47.31% | Mar 31, 2024 |
| TEKLA LIFE SCIENCES INVESTORS | 0.54% | 256,841 | -230,442 | -47.29% | Mar 31, 2024 |
| BRIDGEWAY FUNDS INC | 0.01% | 15,961 | - | - | Mar 28, 2024 |
| PRIMECAP Odyssey Funds | 0.00% | 10,000 | - | - | Jan 31, 2024 |
| Advisors Preferred Trust | 0.00% | 8,262 | 8,262 | - | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 96,630 | - | - | Feb 29, 2024 |
| TRUST FOR PROFESSIONAL MANAGERS | 0.00% | 82,503 | 25,744 | 45.36% | Feb 29, 2024 |
| PROSHARES TRUST | 0.00% | 9,833 | - | - | Feb 29, 2024 |
| iSHARES TRUST | 0.00% | 613,897 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 19,600 | 19,600 | - | Mar 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 28,300 | 28,237 | 44820.63% | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 1,007 | - | - | Mar 28, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 2,169 | - | - | Jan 31, 2024 |
| John Hancock Funds II | 0.00% | 28,200 | 28,200 | - | Feb 29, 2024 |
Mereo BioPharma Group's largest mutual fund holder by % of total assets is "Tema ETF Trust", owning 521.78K shares, compromising 11.69% of its total assets.
Mereo BioPharma Group Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 78 | -7.14% |
| 31 Mar, 24 | 84 | 25.37% |
| 31 Dec, 23 | 67 | 17.54% |
| 30 Sep, 23 | 57 | 3.64% |
| 30 Jun, 23 | 55 | -6.78% |
| 31 Mar, 23 | 59 | -3.28% |
| 31 Dec, 22 | 61 | - |
| 30 Sep, 22 | 61 | -4.69% |
| 30 Jun, 22 | 64 | 14.29% |
| 31 Mar, 22 | 56 | -21.13% |
| 31 Dec, 21 | 71 | 12.70% |
| 30 Sep, 21 | 63 | -12.50% |
| 30 Jun, 21 | 72 | 1.41% |
| 31 Mar, 21 | 71 | 54.35% |
| 31 Dec, 20 | 46 | 100.00% |
| 30 Sep, 20 | 23 | 9.52% |
| 30 Jun, 20 | 21 | 133.33% |
| 31 Mar, 20 | 9 | -18.18% |
| 31 Dec, 19 | 11 | -21.43% |
| 30 Sep, 19 | 14 | -12.50% |
| 30 Jun, 19 | 16 | - |
As of 30 Jun 24, 78 institutions are holding Mereo BioPharma Group's shares, representing a decrease of -7.14% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 100,501,891 | 19.61% |
| 31 Mar, 24 | 84,026,001 | 6.98% |
| 31 Dec, 23 | 78,543,746 | 11.37% |
| 30 Sep, 23 | 70,527,257 | 9.01% |
| 30 Jun, 23 | 64,699,909 | 6.39% |
| 31 Mar, 23 | 60,814,076 | -1.24% |
| 31 Dec, 22 | 61,576,684 | -9.44% |
| 30 Sep, 22 | 67,996,638 | -8.41% |
| 30 Jun, 22 | 74,241,626 | -17.19% |
| 31 Mar, 22 | 89,652,670 | -2.06% |
| 31 Dec, 21 | 91,534,524 | 3.71% |
| 30 Sep, 21 | 88,263,365 | -2.50% |
| 30 Jun, 21 | 90,529,719 | -0.91% |
| 31 Mar, 21 | 91,360,241 | 56.75% |
| 31 Dec, 20 | 58,284,395 | 276.71% |
| 30 Sep, 20 | 15,471,837 | 112.65% |
| 30 Jun, 20 | 7,275,733 | 121.78% |
| 31 Mar, 20 | 3,280,637 | 163.64% |
| 31 Dec, 19 | 1,244,380 | -30.19% |
| 30 Sep, 19 | 1,782,499 | -1.00% |
| 30 Jun, 19 | 1,800,467 | - |
Mereo BioPharma Group (MREO) has 100.50M shares outstanding as of 30 Jun 24, up 19.61% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 14.35% | 8869104.72% |
| 31 Mar, 24 | 0.01% | 0.00% |
| 31 Dec, 23 | 65.11% | 1.91% |
| 30 Sep, 23 | 58.46% | 2.03% |
| 30 Jun, 23 | 53.63% | 2.11% |
| 31 Mar, 23 | 50.41% | 1.93% |
| 31 Dec, 22 | 51.04% | 1.61% |
| 30 Sep, 22 | 56.36% | 1.14% |
| 30 Jun, 22 | 70.33% | 0.98% |
| 31 Mar, 22 | 84.93% | 1.13% |
| 31 Dec, 21 | 86.71% | 1.24% |
| 30 Sep, 21 | 83.61% | 0.47% |
| 30 Jun, 21 | 133.54% | 0.74% |
| 31 Mar, 21 | 134.77% | 1.82% |
| 31 Dec, 20 | 85.98% | 16.51% |
| 30 Sep, 20 | 22.82% | 19.81% |
| 30 Jun, 20 | 10.73% | 45.83% |
| 31 Mar, 20 | 4.84% | 143.63% |
| 31 Dec, 19 | 1.84% | 26.55% |
| 30 Sep, 19 | 2.63% | 37.28% |
| 30 Jun, 19 | 2.66% | - |
As of 30 Jun 24, Mereo BioPharma Group is held by 14.35% institutional shareholders, representing a 8869104.72% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 33 | -35.29% |
| 31 Mar, 24 | 51 | 34.21% |
| 31 Dec, 23 | 38 | 100.00% |
| 30 Sep, 23 | 19 | 5.56% |
| 30 Jun, 23 | 18 | -18.18% |
| 31 Mar, 23 | 22 | -8.33% |
| 31 Dec, 22 | 24 | -7.69% |
| 30 Sep, 22 | 26 | -16.13% |
| 30 Jun, 22 | 31 | 19.23% |
| 31 Mar, 22 | 26 | -27.78% |
| 31 Dec, 21 | 36 | 63.64% |
| 30 Sep, 21 | 22 | -35.29% |
| 30 Jun, 21 | 34 | -27.66% |
| 31 Mar, 21 | 47 | 34.29% |
| 31 Dec, 20 | 35 | 150.00% |
| 30 Sep, 20 | 14 | -12.50% |
| 30 Jun, 20 | 16 | 300.00% |
| 31 Mar, 20 | 4 | 100.00% |
| 31 Dec, 19 | 2 | -66.67% |
| 30 Sep, 19 | 6 | -62.50% |
| 30 Jun, 19 | 16 | - |
33 institutional shareholders have increased their position in MREO stock as of 30 Jun 24 compared to 51 in the previous quarter (a -35.29% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 27 | 125.00% |
| 31 Mar, 24 | 12 | 9.09% |
| 31 Dec, 23 | 11 | -35.29% |
| 30 Sep, 23 | 17 | -5.56% |
| 30 Jun, 23 | 18 | 38.46% |
| 31 Mar, 23 | 13 | 8.33% |
| 31 Dec, 22 | 12 | -25.00% |
| 30 Sep, 22 | 16 | -5.88% |
| 30 Jun, 22 | 17 | 88.89% |
| 31 Mar, 22 | 9 | -40.00% |
| 31 Dec, 21 | 15 | -21.05% |
| 30 Sep, 21 | 19 | 5.56% |
| 30 Jun, 21 | 18 | 157.14% |
| 31 Mar, 21 | 7 | 16.67% |
| 31 Dec, 20 | 6 | 50.00% |
| 30 Sep, 20 | 4 | 33.33% |
| 30 Jun, 20 | 3 | - |
| 31 Mar, 20 | 3 | -40.00% |
| 31 Dec, 19 | 5 | 66.67% |
| 30 Sep, 19 | 3 | - |
| 30 Jun, 19 | - | - |
27 institutional shareholders have reduced their position in MREO stock as of 30 Jun 24 compared to 12 in the previous quarter (a 125.00% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 78 | -7.14% | 100,501,891 | 19.61% | 14.35% | 8869104.72% | 33 | -35.29% | 27 | 125.00% |
| 31 Mar, 24 | 84 | 25.37% | 84,026,001 | 6.98% | 0.01% | 0.00% | 51 | 34.21% | 12 | 9.09% |
| 31 Dec, 23 | 67 | 17.54% | 78,543,746 | 11.37% | 65.11% | 1.91% | 38 | 100.00% | 11 | -35.29% |
| 30 Sep, 23 | 57 | 3.64% | 70,527,257 | 9.01% | 58.46% | 2.03% | 19 | 5.56% | 17 | -5.56% |
| 30 Jun, 23 | 55 | -6.78% | 64,699,909 | 6.39% | 53.63% | 2.11% | 18 | -18.18% | 18 | 38.46% |
| 31 Mar, 23 | 59 | -3.28% | 60,814,076 | -1.24% | 50.41% | 1.93% | 22 | -8.33% | 13 | 8.33% |
| 31 Dec, 22 | 61 | - | 61,576,684 | -9.44% | 51.04% | 1.61% | 24 | -7.69% | 12 | -25.00% |
| 30 Sep, 22 | 61 | -4.69% | 67,996,638 | -8.41% | 56.36% | 1.14% | 26 | -16.13% | 16 | -5.88% |
| 30 Jun, 22 | 64 | 14.29% | 74,241,626 | -17.19% | 70.33% | 0.98% | 31 | 19.23% | 17 | 88.89% |
| 31 Mar, 22 | 56 | -21.13% | 89,652,670 | -2.06% | 84.93% | 1.13% | 26 | -27.78% | 9 | -40.00% |
| 31 Dec, 21 | 71 | 12.70% | 91,534,524 | 3.71% | 86.71% | 1.24% | 36 | 63.64% | 15 | -21.05% |
| 30 Sep, 21 | 63 | -12.50% | 88,263,365 | -2.50% | 83.61% | 0.47% | 22 | -35.29% | 19 | 5.56% |
| 30 Jun, 21 | 72 | 1.41% | 90,529,719 | -0.91% | 133.54% | 0.74% | 34 | -27.66% | 18 | 157.14% |
| 31 Mar, 21 | 71 | 54.35% | 91,360,241 | 56.75% | 134.77% | 1.82% | 47 | 34.29% | 7 | 16.67% |
| 31 Dec, 20 | 46 | 100.00% | 58,284,395 | 276.71% | 85.98% | 16.51% | 35 | 150.00% | 6 | 50.00% |
| 30 Sep, 20 | 23 | 9.52% | 15,471,837 | 112.65% | 22.82% | 19.81% | 14 | -12.50% | 4 | 33.33% |
| 30 Jun, 20 | 21 | 133.33% | 7,275,733 | 121.78% | 10.73% | 45.83% | 16 | 300.00% | 3 | - |
| 31 Mar, 20 | 9 | -18.18% | 3,280,637 | 163.64% | 4.84% | 143.63% | 4 | 100.00% | 3 | -40.00% |
| 31 Dec, 19 | 11 | -21.43% | 1,244,380 | -30.19% | 1.84% | 26.55% | 2 | -66.67% | 5 | 66.67% |
| 30 Sep, 19 | 14 | -12.50% | 1,782,499 | -1.00% | 2.63% | 37.28% | 6 | -62.50% | 3 | - |
| 30 Jun, 19 | 16 | - | 1,800,467 | - | 2.66% | - | 16 | - | - | - |
Mereo BioPharma Group Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Mereo BioPharma Group's stock was made by Sermon Charles on Jun 27 2024, selling 14,202 shares at $3.69 per share (valued at $52.46K).
Mereo BioPharma Group Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 15 | 16 | 93.75% |
| Q1 2024 | 20 | 77 | 25.97% |
15 total buy trades, and 16 total sell trades (buy/sell ratio of 0.94%) were made by Mereo BioPharma Group's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | - | 12 | - |
| Q1 2024 | - | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 12 open market sell trades of Mereo BioPharma Group's stocks.
Mereo BioPharma Group Peer Ownership
| Ticker | Company |
|---|---|
| XFOR | X4 Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PDSB | PDS Biotechnology Corporation |
| HOOK | HOOKIPA Pharma Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| EFTR | eFFECTOR Therapeutics, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| ELEV | Elevation Oncology, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |
MREO Ownership FAQ
Who Owns Mereo BioPharma Group?
Mereo BioPharma Group is owned by institutional shareholders (14.35%), insiders (1.03%), and public (84.62%). The largest institutional shareholder of Mereo BioPharma Group is RUBRIC CAPITAL MANAGEMENT LP (2.19% of total shares) and the top mutual fund owner is Tema ETF Trust (11.69% of total shares).
Who are the major institutional shareholders of Mereo BioPharma Group?
Mereo BioPharma Group's major institutional shareholders are RUBRIC CAPITAL MANAGEMENT LP, ADAGE CAPITAL PARTNERS GP, L.L.C., ROCK SPRINGS CAPITAL MANAGEMENT LP, MANGROVE PARTNERS, and JANUS HENDERSON GROUP PLC. The top five shareholders own together 7.57% of the company's share outstanding.
How many Mereo BioPharma Group shareholders are there?
As of Jun 2024, there are 78 institutional shareholders of Mereo BioPharma Group.
What percentage of Mereo BioPharma Group is owned by RUBRIC CAPITAL MANAGEMENT LP?
RUBRIC CAPITAL MANAGEMENT LP owns 15.31M shares of Mereo BioPharma Group, representing 2.19% of the company's total shares outstanding, valued at $55.11M (as of Jun 2024).
What percentage of Mereo BioPharma Group is owned by ADAGE CAPITAL PARTNERS GP, L.L.C?
As of Jun 2024, ADAGE CAPITAL PARTNERS GP, L.L.C holds 11.79M shares of Mereo BioPharma Group (MREO), compromising 1.68% of the company, valued at $42.45M.
What percentage of Mereo BioPharma Group is owned by ROCK SPRINGS CAPITAL MANAGEMENT LP?
ROCK SPRINGS CAPITAL MANAGEMENT LP is the third largest holder of Mereo BioPharma Group. The company owns 9.28M of the company's shares outstanding (worth $33.42M).